Navigation Links
Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
Date:1/13/2012

om existing therapies and therapies that are currently under development, including therapies that are significantly less expensive than KRYSTEXXA; our ability to gain market acceptance for KRYSTEXXA among physicians, patients, health care payors and others in the medical community; whether we are able to obtain financing, if needed; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT-G

 Contact:

 Mary Coleman

Kelly Sullivan / Jennifer Friedman Savient Pharmaceuticals, Inc.

Joele Frank, Wilkinson Brimmer Katcher information@savient.com

ksullivan@joelefrank.com / jfriedman@joelefrank.com(732) 418-9300

(212) 355-4449 
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
4. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
6. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
7. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
8. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
9. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
10. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising Phase 1/2 ... mda-7/IL-24 tumor,suppressor agent, in patients with advanced solid ... today at the,annual meeting of the American Society ... INGN 241 induced killing in all treated,tumors, including ...
... Company Planning to Initiate Phase 2 Trials ... in Q307 -, SOUTH SAN FRANCISCO, Calif., ... , a,biopharmaceutical company focused on oncology, today ... of two Phase 1,dose-escalating trials of picoplatin, ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... NATIONS, New York (PRWEB) October 19, 2014 ... United Nations Population Fund, welcomes news of a ceasefire ... of the more than 200 girls who were kidnapped ... "These girls have languished in captivity long enough, and ... families, schools and communities," stated Dr. Osotimehin. , "We ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Kan., Jan. 28 Fort Dodge Animal Health,a ... the American Association of Equine,Practitioners (AAEP) recently announced ... raise awareness regarding the health of horses.,Americashealthyhorse.com provides ... The America,s Healthy Horse Web site will aide ...
... -- The Cystic Fibrosis Foundation reported today that key ... including lung function and nutritional status -- are rising ... fact, the outlook for people with CF continues to ... accelerating due to quality improvement programs spearheaded by the ...
... To support,Pennsylvanians who made a New Year,s resolution ... announced that Governor Edward G.,Rendell has proclaimed Jan. 28 ... "Determined to Quit Week is all about motivating Pennsylvanians ... Secretary of,Health Dr. Calvin B. Johnson. "For anyone who ...
... to Expand Profile with Area Representatives, TAMPA, ... leading study program, announces a new program to ... Area,Representatives will travel to massage schools nationwide to ... so comprehensive that,Massage Prep guarantees passage of the ...
... ... Presenting at the UBS Global Healthcare Services Conference on Tuesday, ... February 12, 2008, CINCINNATI, Jan. ... the,LasikPlus brand, announced today upcoming investment community events., Fourth Quarter & Full-Year 2007 ...
... Russian women who smoke has more than doubled since the ... In 1992, seven per cent of women smoked, compared to ... the number of men who smoke has risen from 57 ... the study, published in the journal Tobacco Control, blame the ...
Cached Medicine News:Health News:Fort Dodge Animal Health and the American Association of Equine Practitioners Launch Educational Web Site 2Health News:Cystic Fibrosis Foundation reports upward trend for key health outcomes 2Health News:Massage Prep(TM) Announces Outreach Program 2Health News:LCA-Vision Announces Upcoming Investment Community Events 2Health News:Number of Russian women smokers has doubled since Soviet collapse 2
Leica M500 MS3 robotic stand for neuro, spine surgery and ENT. Motorized XY-movement for precise positioning of the optical axis in eight directions, inclination and tilt....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
... provides surgeons with brighter, crisper, magnified views ... for many minimally invasive spine procedures. It ... point of contact. The first graphical touchscreen ... allows intuitive user guidance similar to that ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
Medicine Products: